海森药业发布前三季度业绩，归母净利润8820.96万元，增长1.45%

Core Viewpoint - Haosen Pharmaceutical (001367.SZ) reported a year-on-year revenue increase of 12.13% for the first three quarters of 2025, reaching 359 million yuan [1] Financial Performance - The company's net profit attributable to shareholders was 88.21 million yuan, reflecting a year-on-year growth of 1.45% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 84.76 million yuan, showing a year-on-year decrease of 1.56% [1] - Basic earnings per share stood at 0.59 yuan [1]